Recent advances in the pharmacogenomics of pain and headache

Neurological Sciences

Volumn 28, Issue SUPPL. 2, 2007, Pages

  Montagna, Pasquale ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Headache; Migraine; Pain; Pharmacogenetics; Pharmacogenomics

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BUTORPHANOL; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 3A5; EXCITATORY AMINO ACID TRANSPORTER 1; FENTANYL; GABAPENTIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HLA DR ANTIGEN; INDOMETACIN; MORPHINE; NALBUPHINE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNN3; PREGABALIN; PROTEIN SCN1A; PROTEIN SCN9A; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ALLELE; ANTINOCICEPTION; ARTICLE; CANCER PAIN; CHRONIC PAIN; CLUSTER HEADACHE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG METABOLISM; FAMILIAL HEMIPLEGIC MIGRAINE; GENETIC VARIABILITY; HEADACHE; HUMAN; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PHARMACOGENOMICS;

ANALGESICS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; ENZYMES; GENETIC PREDISPOSITION TO DISEASE; HEADACHE DISORDERS; HUMANS; PAIN; PHARMACOGENETICS; SODIUM CHANNELS;

EID: 34249311025     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0778-0     Document Type: Article

References (24)

1. Ophoff RA, van den Maagdenberg AMJM, Roon KI et al (2001) The impact of pharmacogenetics for migraine. Eur J Pharmacol 413:1-10
2. Severino G, Chillotti C, Stochino ME, Del Zompo M (2003) Pharmacogenomics: State of the research and perspectives in clinical application. Neurol Sci 24[Suppl 2]:S146-S148
3. Montagna P, Pierangeli G, Cevoli S et al (2005) Pharmacogenetics of headache treatment. Neurol Sci 26[Suppl 2]:S143-S147
4. Wilson SG, Bryant CD, Lariviere WR et al (2003) The heritability of antinociception II: Pharmacogenetic mediation of three over-the-counter analgesics in mice. J Pharmacol Exp Ther 305:755-764
5. Terner JM, Lomas LM, Smith ES et al (2003) Pharmaco genetic analysis of sex differences in opioid antinociception in rats. Pain 106:381-391
6. Chesler EJ, Ritchie J, Kokayell A et al (2003) Genotypedependence of gabapentin and pregabalin sensitivity: The pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 106:325-335
7. Classen DC, Pestotnik SL, Evans RS et al (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277:301-306
8. Phillips KA, Veenstra DL, Oren E et al (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286:2270-2279
9. Rakvag TT, Klepstad P, Baar C et al (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73-78
10. Jin M, Gock S, Jannetto PJ et al (2005) Pharmacogenomics as molecular autopsy for forensic toxicology: Genotyping cytochrome P450 3A4·1B and 3A5·3 for 25 fentanyl cases. J Anal Toxicol 29:590-598
11. Wang GX, Zhang H, He FF, Fang XM (2006) Effect of the CYP2D6·10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 62:927-931
12. Cox JJ, Reimann F, Nicholas AK et al (2006) An SCN9A channelopathy causes congenital inability to experience pain. Nature 444:894-898
13. Fertleman CR, Baker MD, Parker KA et al (2006) SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 52:767-774
14. Catterall WA, Yu FH (2006) Painful channels. Neuron 52:743-744
15. Tegeder I, Costigan M, Griffin RS et al (2006) GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 12:1269-1277
16. Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24:1-160
17. Curtain RP, Lea RA, Tajouri L et al (2005) Analysis of chromosome 1 microsatellite markers and the FHM2-ATP1A2 gene mutations in migraine pedigrees. Neurol Res 27:647-652
18. Kirchmann M, Thomsen LL, Olesen J (2006) The CACNA1A and ATP1A2 genes are not involved in dominantly inherited migraine with aura. Am J Med Genet B Neuropsychiatr Genet 141:250-256
19. Netzer C, Todt U, Heinze A et al (2006) Haplotype-based systematic association studies of ATP1A2 in migraine with aura. Am J Med Genet B Neuropsychiatr Genet 141:257-260
20. Dichgans M, Freilinger T, Eckstein G et al (2005) Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366:371-377
21. Jen JC, Wan J, Palos TP et al (2005) Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 65:529-534
22. Russo L, Mariotti P, Sangiorgi E et al (2005) A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am J Hum Genet 76:327-333
23. Nyholt DR, Morley KI, Ferreira MA et al (2005) Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet 77:500-512
24. Aridon P, D'Andrea G, Rigamonti A et al (2004) Elusive amines and cluster headache: Mutational analysis of trace amine receptor cluster on chromosome 6q23. Neurol Sci 25[Suppl 3]:S279-S280